Drug Pharmacology

Gablofen

Payments companies reported to CMS as associated with Gablofen. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.1Massociated payments (2023-2025)
534clinicians with associated payments
2companies reporting

By year

2023 $286K
2024 $446K
2025 $328K

Payments reported as associated with Gablofen, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Physical Medicine & Rehabilitation $832K
Pediatric Rehabilitation Medicine $75K
Brain Injury Medicine (Physical Medicine & Rehabilitation) $62K
Family $21K
Nurse Practitioner $15K
Neurology (Psychiatry & Neurology) $7,064

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Gablofen

These are the largest totals companies reported as associated with Gablofen. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Zachary Bohart Burlington, MA Physical Medicine & Rehabilitation $357,222.04
Christopher Cronsell Milwaukee, WI Physical Medicine & Rehabilitation $135,474.56
Ravi Kasi Chicago, IL Physical Medicine & Rehabilitation $67,286.68
Monica Verduzco-Gutierrez San Antonio, TX Brain Injury Medicine (Physical Medicine & Rehabilitation) $60,864.24
Elizabeth Moberg Wolff Wauwatosa, WI Pediatric Rehabilitation Medicine $60,165.68
Jose Urquidez Austin, TX Physical Medicine & Rehabilitation $50,205.04
Robert Friedman Boise, ID Physical Medicine & Rehabilitation $44,062.44
Andrea Toomer Marrero, LA Physical Medicine & Rehabilitation $36,640.80
Lizette Alvarez Saint Louis, MO Physical Medicine & Rehabilitation $31,185.76
Bryan Le Bronx, NY Physical Medicine & Rehabilitation $21,439.92

Prescribed Gablofen?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.